



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

- 6 Hwang H, Lee JK, Choi SM, et al. Efficacy of lower dose pirfenidone for idiopathic pulmonary fibrosis in real practice: a retrospective cohort study. *Korean J Intern Med (Korean Assoc Intern Med)* 2022; **37**: 366–76.
- 7 Peljto AL, Selman M, Kim DS, et al. The *MUC5B* promoter polymorphism is associated with idiopathic pulmonary fibrosis in a Mexican cohort but is rare among Asian ancestries. *Chest* 2015; **147**: 460–64.
- 8 Proudman SM, Huq M, Stevens W, et al. What have multicentre registries across the world taught us about the disease features of systemic sclerosis? *J Scleroderma Relat Disord* 2017; **2**: 169–82.
- 9 Anantham D, Ong SJ, Chuah KL, Fook-Chong S, Hsu A, Eng P. Sarcoidosis in Singapore: epidemiology, clinical presentation and ethnic differences. *Respirology* 2007; **12**: 355–60.
- 10 Inoue Y, Wells AU, Song JW, et al. Nintedanib in Asian patients with progressive fibrosing interstitial lung diseases: results from the INBUILD trial. *Respirology* 2023; published online Jan 15. <https://doi.org/10.1111/resp.14452>.



## Association of SARS-CoV-2 infection and persistence with long COVID

Published Online  
May 10, 2023  
[https://doi.org/10.1016/S2213-2600\(23\)00142-X](https://doi.org/10.1016/S2213-2600(23)00142-X)

Long COVID or post-COVID-19 condition can affect anyone exposed to SARS-CoV-2, regardless of age or severity of the original symptoms, characterised by long-term health problems persisting or appearing after the typical recovery period of COVID-19. WHO define long COVID as: “the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanation”. Although many studies on long COVID are underway, its pathogenesis remains unclear. As COVID-19 becomes increasingly prevalent in the coming years as the number of people who have been infected with SARS-CoV-2 increases, it is essential that we comprehensively understand the pathogenesis of long COVID to help patients, policymakers, and health-care systems develop and implement future strategies for prevention, treatment, and health-resource planning.

The longest bout of SARS-CoV-2 infection recorded to date was a patient in the UK who tested positive for COVID-19 for 505 days until her death.<sup>1</sup> 5 years after the end of the Ebola virus outbreak in 2016, the virus re-emerged in people who previously had Ebola virus disease in 2021.<sup>2</sup> Similarly, people who previously had West Nile virus infection with chronic symptoms still had positive urine RT-PCR tests 1–6–7 years after recovery from acute illness. Whether SARS-CoV-2 can also reactivate and retransmit after several years of dormancy is not yet known.

Researchers at the National Institutes of Health investigated the replication competence, persistence, and evolution of SARS-CoV-2 in human cells and looked for relevant histopathological features in infected tissues by performing autopsies on 44 COVID-19 cases. They found SARS-CoV-2 RNA widely distributed in


84 distinct anatomical locations up to 230 days after infection.<sup>3</sup> Surprisingly, viral persistence was detected by high-sensitivity droplet digital PCR (ddPCR) across multiple tissue samples among all deceased with infection cases despite being undetectable in plasma.<sup>3</sup> These findings suggest that the viral load in patients with COVID-19 might be low but still detectable in biospecimens with the appropriate assays following acute SARS-CoV-2 infection. In addition, the detection of subgenomic RNA, a marker of recent virus replication, and the isolation of replication-competent SARS-CoV-2 from respiratory and non-respiratory tissues, suggest that viral replication might occur for several months after the initial infection.<sup>3</sup> A Spanish group’s autopsy study of 27 COVID-19 patients with long disease duration showed the presence of persistent SARS-CoV-2 RNA in autopsy tissue samples from patients that had a median duration of 39 days of infection (ranging 9 to 108 days).<sup>4</sup> These results and other case reports also suggest that immunocompromised patients, such as those with haematological malignancies, are more susceptible to persistent viral infection given their inability to mount a robust immune response. Importantly, Italian researchers reported on 27 consecutive patients who ostensibly recovered from COVID-19 but whose clinical condition progressively worsened despite testing negative for nasopharyngeal swabs or bronchoalveolar lavage samples. Subsequent autopsies revealed continued shedding of SARS-CoV-2 RNA in their lung tissue samples for up to 300 days after remission from acute infection, and people who previously had COVID-19 were more likely to report persistent post-COVID symptoms.<sup>5</sup> These results suggest that the SARS-CoV-2 virus had not been completely cleared from these patients. In addition

to autopsy studies, researchers in Singapore found residual viral protein and RNA in the appendix, skin, and breast tissue of two patients who developed long COVID symptoms 163 and 426 days after the onset of symptoms, respectively.<sup>6</sup> Similarly, researchers in Spain showed that SARS-CoV-2 was still present in surgically resected intestinal specimens 6 months after COVID-19 rehabilitation, despite negative nasopharyngeal PCR results.<sup>7</sup> Moreover, researchers in the USA and Austria found that viral RNA persisted in the stool of COVID-19 patients 7 months after diagnosis, which might imply that the gut of individuals with long COVID is a persistent viral reservoir.<sup>8,9</sup> Furthermore, a USA-based group reported that gastrointestinal symptoms (abdominal pain, nausea, and vomiting) are associated with the persistence of faecal SARS-CoV-2 RNA, 7 months after diagnosis.<sup>8</sup> Slovakian researchers reported the presence of SARS-CoV-2 in the cerebrospinal fluid of patients with long COVID.<sup>10</sup> The persistence of SARS-CoV-2 in the human olfactory neuroepithelium and associated inflammation were the cause of long COVID symptoms or relapses in post-COVID symptoms, such as loss of smell, as reported by researchers in France.<sup>11</sup> Time from the first onset of symptoms to inclusion in the study ranged from 110 to 196 days. A USA-based group described the presence of SARS-CoV-2 RNA and protein in the stools of 14 premature newborn babies delivered with negative

nasal PCR results for SARS-CoV-2, whose mothers had been infected during pregnancy.<sup>12</sup> In another USA study, circulating SARS-CoV-2 spike antigen was detected in 60% of a cohort of 37 patients with long COVID within 12 months of diagnosis compared with those with non-long COVID.<sup>13</sup> These patients with non-long COVID were PCR confirmed COVID-19 convalescents with no reported prolonged symptoms sampled after diagnosis.

The presented evidence suggests that the duration of SARS-CoV-2 infection in patients can persist considerably longer than suggested by PCR-negative tests on nasopharyngeal swabs or bronchoalveolar lavage fluids. A US study including 40 947 participants with SARS-CoV-2 reinfection (two or more infections), 443 588 participants with a single SARS-CoV-2 infection, and 5 334 729 participants with no SARS-CoV-2 infection indicated that reinfection further increases risks of death, hospitalisation, and sequelae in multiple organ systems in the acute and post-acute phases.<sup>14</sup> Persistent low-grade multisystem injury in both adults and children might result from lingering SARS-CoV-2 infection or reinfection. In another study, the circulating SARS-CoV-2 components, spike protein, and viral RNA fragments persisted for up to 1 year or longer after SARS-CoV-2 acute infection in patients with long COVID, whereas these viral components decreased or were totally absent in convalescent patients with COVID-19, as shown by ddPCR and spike protein ELISA techniques.<sup>15</sup>

See Online for appendix



**Figure:** Examples of long COVID driven by persistence of SARS-CoV-2

Possible pathogenic mechanisms of persistent virus that might lead to chronic inflammation, immune dysfunction, microvascular endothelial damage, and microthrombosis seen in long COVID.

These findings provide further evidence that there might be a correlation between the length of time the virus stays in the body and the risk of long COVID (appendix p 1). Therefore, rapid viral elimination in patients with persistent SARS-CoV-2 virus could be crucial. We summarised the approved and ongoing, but unpublished, randomised trials on the nirmatrelvir with ritonavir (a SARS-CoV-2 main protease inhibitor) treatment for long COVID (appendix p 3) or persistence of SARS-CoV-2 in post-COVID-19 patients (appendix p 4) listed on ClinicalTrials.gov. The results of a recent observational study on nirmatrelvir with ritonavir and long COVID are promising and intriguing, and demand further investigation. The use of nirmatrelvir with ritonavir might eliminate viral reservoirs and alleviate long COVID symptoms.

Here we present a pathophysiological model of long COVID based on the persistence of SARS-CoV-2 virus that triggers a dysregulation of the immune system, followed by increased release of inflammatory cytokines and abnormal endothelial damage, ultimately leading to the development of chronic inflammation, vascular damage, hypercoagulability, microthrombosis, and multiorgan symptoms (figure). Anti-SARS-CoV-2 and other applicable therapies might contribute to viral clearance or to the reduction of inflammation to improve long COVID symptoms. Here, we present recommendations and future directions for a more effective response to long COVID (appendix p 5). We believe that a comprehensive understanding of the pathogenesis of long COVID will provide an opportunity for better outcomes for all patients experiencing similar conditions.

CY and SJT report a grant from the Canadian Institutes of Health Research (177747) as payment to their institution to support their work in Canada. All other authors declare no competing interests.

Chengliang Yang, Hedi Zhao, Estefanía Espín, \*Scott J Tebbutt  
scott.tebbutt@hli.ubc.ca

Prevention of Organ Failure Centre of Excellence, Vancouver, BC, Canada (CY, EE, SJT); Centre for Heart Lung Innovation, Providence Research, St Paul's Hospital, Vancouver, BC, Canada (CY, EE, SJT); Division of Respiratory Medicine, Department of Medicine, University of British Columbia, Vancouver, BC V6Z 1Y6, Canada (CY, SJT); Department of Surgery, University of British Columbia, Vancouver, BC, Canada (HZ)

- 1 European Society of Clinical Microbiology and Infectious Diseases. Longest known COVID-19 infection—505 days—described by UK researchers. April 21, 2022. [www.eurekalert.org/news-releases/950412](http://www.eurekalert.org/news-releases/950412) (accessed Jan 16, 2023).
- 2 Keita AK, Koundouno FR, Faye M, et al. Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. *Nature* 2021; **597**: 539–43.
- 3 Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. *Nature* 2022; **612**: 758–63.
- 4 Caniego-Casas T, Martínez-García L, Alonso-Riño M, et al. RNA SARS-CoV-2 persistence in the lung of severe COVID-19 patients: a case series of autopsies. *Front Microbiol* 2022; **13**: 824967.
- 5 Bussani R, Zentilin L, Correa R, et al. Persistent SARS-CoV-2 infection in patients seemingly recovered from COVID-19. *J Pathol* 2023; **259**: 254–63.
- 6 Goh D, Lim JCT, Fernández SB, et al. Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID. *Front Immunol* 2022; **13**: 939989.
- 7 Martín-Cardona A, Lloreta Trull J, Alberó-González R, et al. SARS-CoV-2 identified by transmission electron microscopy in lymphoproliferative and ischaemic intestinal lesions of COVID-19 patients with acute abdominal pain: two case reports. *BMC Gastroenterol* 2021; **21**: 334.
- 8 Natarajan A, Zlitni S, Brooks EF, et al. Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection. *Med* 2022; **3**: 371–87.e9.
- 9 Zollner A, Koch R, Jukic A, et al. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. *Gastroenterology* 2022; **163**: 495–506.e8.
- 10 Vizlayová D, Sojka M, Dobrodenková S, et al. SARS-CoV-2 RNA in the cerebrospinal fluid of a patient with long COVID. *Ther Adv Infect Dis* 2021; **8**: 20499361211048572.
- 11 de Melo GD, Lazarini F, Levallois S, et al. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. *Sci Transl Med* 2021; **13**: eabf8396.
- 12 Jin JC, Ananthanarayanan A, Brown JA, et al. SARS CoV-2 detected in neonatal stool remote from maternal COVID-19 during pregnancy. *Pediatr Res* 2023; **22**: 1375–82.
- 13 Swank Z, Senussi Y, Manickas-Hill Z, et al. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. *Clin Infect Dis* 2023; **76**: e487–90.
- 14 Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. *Nat Med* 2022; **28**: 2398–2405.
- 15 Craddock V, Mahajan A, Krishnamachary B, et al. Persistent circulation of soluble and extracellular vesicle-linked spike protein in individuals with postacute sequelae of COVID-19. *J Med Virol* 2023; **95**: e28568.



## Multimodal, patient-centred symptom control: a strategy to replace sedation in the ICU

Published Online

May 12, 2023

[https://doi.org/10.1016/S2213-2600\(23\)00141-8](https://doi.org/10.1016/S2213-2600(23)00141-8)

Worldwide, more than 20 million patients annually receive mechanical ventilation in an intensive care unit (ICU).<sup>1</sup> Infusions of sedating medications (eg, benzodiazepines, dexmedetomidine, opioids, or propofol) or volatile anaesthetics (eg, isoflurane) are

commonly used in mechanically ventilated patients in high-income countries and their use increased during the COVID-19 pandemic.<sup>2</sup> Sedation—defined as the administration of a sedating medication to impair consciousness—is a common practice in the ICU due to